Rowan University

Rowan Digital Works
Faculty Scholarship for the College of Science &
Mathematics

College of Science & Mathematics

11-30-2018

Binding of Telomestatin, TMPyP4, BSU6037, and BRACO19 to a
Telomeric G-Quadruplex-Duplex Hybrid Probed by All-Atom
Molecular Dynamics Simulations with Explicit Solvent.
Holli-Joi Sullivan
Carolyn Readmond
Christina Radicella
Victoria Persad
Thomas J Fasano

See next page for additional authors

Follow this and additional works at: https://rdw.rowan.edu/csm_facpub
Part of the Chemistry Commons

Recommended Citation
Sullivan, H-J., Readmond, C., Radicella, C., Persad, V., Fasano, T., & Wu, C. (2018) Binding of Telomestatin,
TMPyP4, BSU6037, and BRACO19 to a Telomeric G‑Quadruplex−Duplex Hybrid Probed by All-Atom
Molecular Dynamics Simulations with Explicit Solvent. ACS Omega 2018, 3, 14788-14806.

This Article is brought to you for free and open access by the College of Science & Mathematics at Rowan Digital
Works. It has been accepted for inclusion in Faculty Scholarship for the College of Science & Mathematics by an
authorized administrator of Rowan Digital Works.

Authors
Holli-Joi Sullivan, Carolyn Readmond, Christina Radicella, Victoria Persad, Thomas J Fasano, and Chun
Wu

This article is available at Rowan Digital Works: https://rdw.rowan.edu/csm_facpub/122

This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.

Article
Cite This: ACS Omega 2018, 3, 14788−14806

http://pubs.acs.org/journal/acsodf

Binding of Telomestatin, TMPyP4, BSU6037, and BRACO19 to a
Telomeric G‑Quadruplex−Duplex Hybrid Probed by All-Atom
Molecular Dynamics Simulations with Explicit Solvent
Holli-Joi Sullivan,† Carolyn Readmond,† Christina Radicella,† Victoria Persad,‡ Thomas J. Fasano,‡
and Chun Wu*,†,‡
Chemistry & Biochemistry and ‡Department of Molecular & Cellular Biosciences, College of Science and Mathematics, Rowan
University, Glassboro, New Jersey 08028, United States

Downloaded via ROWAN UNIV on December 13, 2018 at 14:12:55 (UTC).
See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.

†

S Supporting Information
*

ABSTRACT: A promising anticancer therapeutic strategy is
the stabilization of telomeric G-quadruplexes using Gquadruplex-binding small molecules. Although many Gquadruplex-speciﬁc ligands have been developed, their low
potency and selectivity to G-quadruplexes over duplex remains
unsolved. Recently, a crystal structure of a telomeric 3′
quadruplex−duplex hybrid was reported and the quadruplex−
duplex interface was suggested to a good target to address the
issues. However, there are no high-resolution complex
structures reported for G-quadruplex ligands except for a
docked BSU6037. In this study, molecular dynamic (MD)
binding simulations with a free ligand were used to study
binding poses and dynamics of four representative ligands:
telomestatin, TMPyP4, BSU6037, and BRACO19. The MD
data showed that BSU6037 was able to fully intercalate into the interface whereas TMPyP4 and BRACO19 could only maintain
partial intercalation into the interface and telomestatin only binds at the quadruplex and duplex ends. Both linear ligands,
BSU6037 and BRACO19, were able to interact with the interface, yet they were not selective over duplex DNA. The DNA
geometry, binding modes, and binding pathways were systematically characterized, and the binding energy was calculated and
compared for each system. The interaction of the ligands to the interface was by the means of an induced-ﬁt binding mechanism
rather than a lock−key mechanism, consisting of the DNA unfolding at the interface to allow entrance of the drug and then the
refolding and repacking of the DNA and the ligand to further stabilize the G-quadruplex. On the basis of the ﬁndings in this
study, modiﬁcations were suggested to optimize the interface binding for TMPyp4 and telomestatin.

■

INTRODUCTION
A promising anticancer therapeutic strategy is the stabilization
of telomeric G-quadruplexes using quadruplex-binding small
molecules.1−4 G-quadruplexes are formed from the stacking of
guanine (G) tetrads via Hoogsteen base pairing in G-rich
sequences.3−12 Human telomeres appearing at the end of
chromosomes consist of a 3′ single-stranded TTAGGG repeat
overhang.2,10−18 This TTAGGG repeat overhang has the
ability to form G-quadruplexes. During cell division, the
(TTAGGG)n sequence is progressively shortened until a
growth-arrest state and eventual senescence, the complete
stopping of cell division, is reached.4,12,16,18−22 When
senescence is bypassed due to the absence of cell cycle
checkpoints, a cell then reaches a state of crisis where it
undergoes uncontrolled growth.2,4,9,12,14,19,22,23 The overexpression of telomerase, a reverse transcriptase that lengthens
telomeres,2−4,9,12,18,19,24 results in the bypass of senescence and
thus indeﬁnite growth of cancerous cells.9,10,12,13,17−19,25 Gquadruplexes have been shown to inhibit telomerase by making
© 2018 American Chemical Society

the 3′ overhang inaccessible to the telomerase RNA
template.9,16,26−29 It has also been shown that G-quadruplex
speciﬁc ligands compete with the protection of telomere
protein 1 binding, where the binding of the ligands leads to a
series of events: the uncapping of telomeres, DNA damage
response signaling, and eventual apoptosis of the mutated
cells.23,30−32 Consequently, the stabilization of telomeric Gquadruplexes is a viable therapeutic strategy to treat cancers.12
Furthermore, the over-representation of G-quadruplexes in
cancer cells21,33−37 makes them cancer-speciﬁc targets.31
Because of this, many studies have been performed on the
telomeric and promoter G-quadruplexes with various Gquadruplex speciﬁc ligands to inhibit cancer cell
growth.1,2,9,15,16,22,27,38−47
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Figure 1. Structures of the telomeric DNA quadruplex−duplex hybrid (A), telomestatin (B), TMPyP4 (C), BSU6037 (D), and BRACO19 (E).

quadruplexes.76,77 It is clear that potency, selectivity, and other
properties need to be further improved to convert these
compounds to therapeutic agents.
The detailed binding poses of multiple G-quadruplex ligands
have been experimentally and computationally characterized;
these studies suggested two well-known binding poses: end-toend stacking (top or bottom stacking) and groove binding.9,10,21,22,31,33,41,43−45,78−80 The main binding interactions
have been shown to be π−π stacking of the aromatic core of
small ligands with the G-quartet, which is best achieved in endto-end stacking.74 However, since terminal G-quartets are
present in the majority of G-quadruplexes, achieving selectivity
to a distinct G-quadruplex has become another issue.
A recent work by Krauss and others involving Gquadruplexes has begun to focus on targeting the telomeric
3′ junction formed between a G-quadruplex and duplex DNA
as a solution to increase the binding selectivity and potency to
G-quadruplexes over duplexes for G-quadruplex ligands.46 In
their work, a crystal structure of a telomeric 3′ quadruplex−
duplex hybrid formed from putative parallel G-quadruplex and
duplex DNA was reported (Figure 1A) and the junction was
suggested as a more speciﬁc G-quadruplex site that can be
targeted by G-quadruplex ligands.46 To probe the ligand
binding at the quadruplex−duplex interface, a diverse range of
G-quadruplex ligands (BSU6037, BSU6039, BRAC-19,
TMPyP4, and FC4ND10) were selected for ligand soaking
experiments with preformed crystals of the quadruplex−duplex
hybrid. Ligands that did not signiﬁcantly degrade crystal
quality but appeared to bind to the construct were TMPyP4,
Cu-porphyrin, BSU6037, and FC4ND10. However, the
binding pose at the interfaces was not obtained due to
diﬀerent reasons. Binding of TMPyP4 caused a large decrease
in diﬀraction quality (from about 3.0 to 4.3 Å resolution) and a
slight change in cell dimensions. Analysis of diﬀerent Fourier
maps did not show the presence of BSU6037 or Cu-porphyrin
bound to the quadruplex−duplex hybrid, and FC4ND10 was
observed to bind in the duplex region. Since no structural data
is available on ligand binding at the quadruplex−duplex
interface, BSU6037 was docked to a pseudo-ligand-binding site

The class of anticancer drugs in this paper is widely
represented by two structural characterizations: cyclical and
linear. Four ligands (telomestatin, TMPyP4, BSU6037, and
BRACO19 in Figure 1B−E) are used to exemplify ligands of
both structural families within this class of drugs. Telomestatin
and TMPyP4 are representative of the cyclical ligands;
BSU6037 and BRACO19 are representative of the linear
ligands. Telomestatin,48−51 TMPyP4,52−55 and
BRACO1956−71 were chosen explicitly because they are the
most studied ligands that are potent against various cancer cell
lines. The ligand BSU6037 was previously docked to the
quadruplex−duplex interface by Krauss et al.46
A large variety of G-quadruplex speciﬁc ligands have been
developed on the following criteria: an aromatic core that
allows π−π stacking to the G-quartet and a side chain that
allows electrostatic interactions with the sugar-phosphate
backbone and ensures solubility.3,4,10−12,17,18,29,31,72 For a
ligand to target G-quadruplexes successfully, its binding
equilibrium constant must be at least 106 M−1 and it also
must be selective over duplex binding by at least 2 orders of
magnitude. The binding properties of three leading ligands
(telomestatin, TMPyP4, and BRCO19) is listed in Table S1 of
the Supporting Information. Telomestatin, a natural product,
shows the highest potency and telomerase inhibition, and it is
also 70 times more selective toward G-quadruplexes than
duplex DNA.26,73 Despite this, telomestatin’s hydrophobicity
and low water solubility impedes its bioavailability, which is an
integral feature in successful drug design.3,31,74 TMPyP4 is a
synthetic ligand designed for G-quadruplex stabilization with
an aﬃnity of 20 × 106 M−1 and a TRAP-LIG EC50 (TRAP: the
telomere repeat ampliﬁcation protocol for telomerase, which is
used for determination of telomerase activity) of 8.9 μM but is
only 2 times more selective to the G-quadruplex than duplex
DNA.21,75 The synthetic acridine, BRACO19, has been
reported to have promising potency, KG4 = 30 × 106 M−1,
and telomeric inhibition, TRAP-LIG EC50 = 6.3 μM, with 10
times more selectivity over duplex DNA.31,32,75 However,
BRACO19 has low membrane permeability and decomposes
quickly, which decreases the binding of BRACO19 to G14789
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Table 1. Molecular Dynamics Simulation Runs
system
IDa
1
2
3
4
5
6
7
8
9

DNA
1
0
0
0
0
1
1
1
1

(5dww)

(5dww)
(5dww)
(5dww)
(5dww)

no. of
ligands
0
1
1
1
1
1
1
1
1

no. of
runs
3
5
5
5
5
19
19
19
19

+
+
+
+

1
1
1
1

no. of water
molecules

ions

box size
(Å)b

drug initial
pose

NPT eq.
(ns)

NVT (ns)

total time
(μs)

6242
1491
1043
2065
1487
18 926
11 298
12 131
15 541

30 K+
0
4 Cl−
2 Cl−
3 Cl−
30 K+
26 K+
28 K+
27 K+

67.7
31.8
37.4
45.8
41.5
94.1
80.2
82.0
88.4

N/A
free
free
free
free
free
free
free
free

1
1
1
1
1
1
1
1
1

1999
499
499
499
499
499/1999
499/1999
499/1999
499 1999

6
2.5
2.5
2.5
2.5
11.5
11.5
11.5
11.5

a

System 1 refers to the free DNA-only and systems 2−5 refer to the free ligand-only simulations (2−5: telomestatin, TMPyP4, BSU6037, and
BRACO19, respectively). Systems 6−9 refer to the free DNA plus free ligand simulations (6−9: telomestatin, TMPyP4, BSU6037, and BRACO19,
respectively). bTriclinic box equivalent to the true truncated octahedral box.

Figure 2. Representative trajectory of the DNA-only simulation and the order parameter plot illustrating the breaking and reforming of hydrogen
bonds (at the quadruplex (1), interface (2), and duplex (3)), RMSD (Å) with reference to the ﬁnal structure (4), K+ to K+ distance (5), and the
MM-GBSA binding energy (ΔE in kcal/mol) (6). 5′ and 3′ of the DNA chain are indicated by a red and blue ball, respectively. K+ ions are
indicated by a yellow ball.

ligand. The MD simulations probed the structure, dynamics,
and interaction of the G-quadruplex−duplex construct with the
ligands in high spatial and temporal resolution.82 Detailed
process information was used to decipher the binding
mechanism. Speciﬁcally, this study utilized the latest AMBER
DNA force ﬁeld (OL15) and drug (GAFF2) force ﬁelds to
simulate the binding process between the ligands and the
human telomeric G-quadruplex−duplex construct from an
initially unbound state (where the ligand is 10 Å away from the
DNA). The binding modes and pathways of each ligand to the
G-quadruplex−duplex DNA were characterized, and then the
molecular mechanics generalized born/surface area (MMGBSA) binding energies of each binding pose were compared.

at the interface that was generated by rotating the
phosphodiester backbone of T17, while maintaining strand
polarity of the G-rich strand. Although the obtained binding
pose of BSU6037 is closely analogous to that observed on a
crystal complex structure formed between BSU6039 and a
bimolecular quadruplex (1L1H),81 lack of structural ﬂexibility
in the docking may limit induced-ﬁt binding modes.
This study aims at furthering molecular modeling investigations with four representative ligands (telomestatin,
TMPyP4, BSU6037, and BRACO19 in Figure 1B−E) binding
to the telomeric 3′ quadruplex−duplex construct in hopes of
characterizing binding poses and their binding mechanisms
using molecular dynamics (MD) binding simulation with a free
14790
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distribution of the twist angle between the two adjacent Gquartets for biomolecular parallel G-quadruplexes is ranged
from 10 to 35°, with a maximum at 31 ± 3°.83 Nonetheless, Hrise and H-twist in G-quadruplex are smaller than those in
standard B-DNA (3.32 Å and 34.3° for H-rise and H-twist,
respectively). Interestingly, the stacking of telomestatin on the
top of the G-quadruplex (Figure 5) did not change these
parameters much (∼3.37 Å, ∼1.79 Å, and ∼15.8°) neither did
the binding of BSU6037 (Figure 7) at the G-quadruplex−
duplex interface (∼3.44 Å, ∼1.92 Å, and ∼16.9°) but the
interaction from TMPyP4 and BRACO19 changed H-rise to
from ∼2.09 to ∼3 Å. Thus, ligand binding can slightly
modulate the G-quadruplex interlayer geometry.
Ligand Binding Did Not Change the Interaction
between K+ and the G-Quadruplex in Cases When K+
Did Not Move Out. Potassium ions play an important role in
stabilizing G-quadruplexes. The distances between a potassium
ion and eight neighboring oxygen atoms and the oxygen−
oxygen distances were calculated, and these values are shown
in Figure S1c,d for the DNA-only system. The values for the
crystal structure and other four DNA−ligand systems are
shown in Tables S2 and S3. The average potassium−oxygen
distance diﬀerence between the crystal structure and the
simulated DNA-only system was within 0.16 Å, which is
comparable to the structural ﬂuctuation (±0.18 Å) observed in
the MD simulations. The average oxygen−oxygen distance
diﬀerence between the crystal structure and simulated DNAonly system was within 0.34 Å, which is slightly larger than the
structural ﬂuctuation (±0.21 Å). Thus, the simulation well
reproduced these distances. The average potassium−oxygen
distance diﬀerence between the simulated DNA-only system
and DNA−ligand systems was within 0.05 Å, which is much
smaller than the structural ﬂuctuation (±0.18 Å) observed in
the MD simulations. The average oxygen−oxygen distance
diﬀerence between the simulated DNA-only system and
DNA−ligand systems was within 0.03 Å, which is slightly
larger than the structural ﬂuctuation (±0.21 Å). Thus, ligand
binding did not change the interaction between K+ and the Gquadruplex when K+ did not move out.
Geometric Characterization of the Duplex Part
Showed That a Normal B-DNA Geometry for Most
Base Pairs Was Maintained, the Ligand Binding on the
Top of the G-Quadruplex or at the G-Quadruplex−
Duplex Interface Did Not Change the Duplex Geometry. Various geometry parameters including base pair-axis, base
pair-step, and paired base−base parameters were calculated, as
detailed in the method section, to characterize the duplex part
for the crystal structure and the ﬁve simulated systems (Table
S4). The values from the ﬁve simulated systems generally agree
with the values from the crystal structure. For example, the
crystal structure has average values of ∼3.3 Å and ∼31° for Hrise and H-twist, respectively. The H-rise for the DNA-only
system, DNA−telomestatin system (top binding), DNA−
TMPyP4 (interface interacting), DNA−BSU6037 (interface
binding), and DNA−BRACO19 (interface interacting) is ∼2.8,
∼3.4, ∼3.0, ∼3.0, and ∼3.1 Å. The H-twists for the DNA-only
system, DNA−telomestatin system (top binding), DNA−
TMPyP4 (interface interacting), DNA−BSU6037 (interface
binding), and DNA−BRACO19 (interface interacting) is ∼30,
∼33, ∼30, ∼30, and ∼32°. All of these values are close to the
values of 3.3 Å and 34° for H-rise and H-twist of B-DNA helix,
respectively. Thus, the helical structure of the duplex was
maintained throughout the MD simulations. This is also

Three major modes of binding were observed for TMPyP4,
BSU6037, and BRACO19: interface intercalation, binding to
the quadruplex, and binding to the duplex. No intercalation
binding mode was observed for telomestatin, but suggestions
on how to alter the telomestatin scaﬀold to allow for interface
intercalation were given. The MM-GBSA binding energy
analysis indicates that the charged aromatic TMPyP4 scaﬀold
was better than both the uncharged aromatic structures
telomestatin and linear structures (BSU6037 and
BRACO19). Additionally, an implication on designing a better
TMPyP4 analog was also discussed (Table 1).

■

RESULTS
Scaﬀold of the Quadruplex−Duplex Hybrid Was
Maintained in the DNA-Only Simulations. To validate
the force ﬁeld for DNA, the DNA-only system was constructed
from the crystal structure (Protein Data Bank (PDB) ID:
5DWW) for stability simulations. Three independent runs for
this DNA-only system were carried for 2.0 μs. DNA backbone
root-mean-square deviation (RMSD) plots and the last
snapshots are shown in Figures S3 and S6, respectively.
Clearly, the DNA hybrid was stable in all three runs, as
indicated by the small root-mean square deviation of the
backbone from the starting crystal structure (RMSD = 2−3 Å).
Neither of the two K+ ions inside the G-quadruplex moved out,
and all of them maintained the initial positions in three runs.
To show more structural details, a representative trajectory
and its order parameters are shown in Figure 2. First, the Gquadruplex was stable, indicated by maintaining ∼8, ∼9, and
∼8 hydrogen bonds for the top, middle, and bottom G4 layers.
Second, the interface was stable, indicated by ∼3 and ∼1
hydrogen bonds for the tribase layer and the A7−T19 pair.
Third, the duplex part was stable, indicated by maintaining ∼2
hydrogen bonds for each base pair in the duplex part. Fourth,
the DNA backbone was stable, indicated by a small RMSD of
∼2.5 Å. Fifth, the two K+ ions inside the quadruplex were
stable, indicated by maintaining the K+ to K+ distance of ∼3.8
Å, with a small ﬂuctuation. Sixth, the calculated relative
conformation energy using MM-GBSA showed ﬂuctuation but
was ﬂat overall.
Geometric Characterization of the G-Quadruplex
Part Showed a Right-Handed Helical Twist of the
Three G4 Layers, the Ligand Binding Can Make Subtle
Changes. Although the scaﬀold of a G-quadruplex has been
extensively studied and classiﬁed into parallel, antiparallel, and
hybrid class, the inter-G4 layer geometry from the MD
simulations has not been thoroughly examined. From the top
view of the G-quadruplex part (Figure S1a), the right-handed
helical rotation of G4 layers was obviously identiﬁed.
Analogous to the right-handed helical rise and twist in Bform DNA, this work has deﬁned and calculated the rise, Hrise, and H-twist, as detailed in the method section for the
crystal structure and ﬁve simulated systems (Table S6). For the
DNA-only simulated system, the rise, H-rise, and H-twist
averaged over the two layer steps (i.e., bottom to middle and
middle to top) are ∼3.44 Å, ∼2.09 Å, and ∼17.6°, respectively,
which are close to the values of the crystal structures (∼3.42 Å,
∼1.13 Å, and ∼10.7°). The slightly larger diﬀerences for H-rise
and H-twist may be attributed to the crystal packing in the
condense phase or the force-ﬁeld artifact. Further comparison
to the solution NMR structure will clarify this issue. This is
supported by a recent bioinformatics study on 74 Gquadruplex structures in the PDB, suggesting that the
14791
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Figure 3. Root-mean-square ﬂuctuation (RMSF) plot of the ﬁve systems (DNA-only, top binding of telomestatin, interface intercalation mode of
BSU6037, and the interface interacting mode of TMPyP4 and BRACO19). The x axis refers to the residue number of the DNA quadruplex hybrid
structure (Figure 1a); the residue 1 of the second chain was missed in the crystal structure.

Figure 4. Major binding modes between ligands and human telomeric quadruplex−duplex (PDB ID: 5DWW). 5′ and 3′ of the DNA chain are
indicated by a red and blue ball, respectively. K+ ions are indicated by yellow balls. Overall population abundance (MM-GBSA binding energy) of
each binding mode is annotated.

Root-Mean-Square Fluctuation (RMSF) Data Showed
That the Three loops (T4, T8, and T12−T13) in the GQuadruplex Part (1−16) and Interface Region (T17−

supported from the DNA backbone dihedral angle and pucker
calculations (Table S5): although there are some subtle
diﬀerences, most values are close to each other.
14792
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Table 2. MM-GBSA Binding Energy of Ligands to the Quadruplex−Duplex DNAa,b,c,d,e,f
ligands (charge state)

binding pose

telomestatin (0)

G-quadruplex
duplex
interface
G-quadruplex
duplex
interface
G-quadruplex
duplex
interface
G-quadruplex
duplex

TMPyP4 (+4)

BSU6037 (+2)

BRACO19 (+3)

ΔVDW
−50.1
−41.4
−68.2
−51.8
−68.4
−52.9
−15.8
−52.9
−37.7
−44.8
−42.2

±
±
±
±
±
±
±
±
±
±
±

ΔSUR
2.0
5.4
3.7
3.1
3.9
5.6
6.7
3.9
3.1
3.5
8.9

−2.7
−2.9
−5.1
−3.4
−4.8
−4.2
−1.6
−4.7
−4.4
−3.3
−4.4

±
±
±
±
±
±
±
±
±
±
±

ΔGBELE
0.1
0.3
0.3
0.2
0.2
0.6
0.7
0.3
0.3
0.4
0.7

18.3
16.4
−11.4
−12.6
−8.0
−6.0
−8.9
−7.3
−19.1
−10.7
−14.5

±
±
±
±
±
±
±
±
±
±
±

1.4
2.8
1.6
1.8
2.0
4.0
3.6
2.8
3.3
3.2
5.3

ΔCONF
−35.9
−2.4
−11.5
−15.1
3.5
−29.2
−33.2
−20.0
−26.1
−24.5
−23.2

±
±
±
±
±
±
±
±
±
±
±

4.5
3.5
5.8
2.9
6.3
0.8
1.0
0.3
2.8
5.9
4.3

ΔTOT
−70.4
−30.3
−96.2
−82.9
−78.5
−92.3
−59.5
−90.6
−87.3
−77.7
−84.3

±
±
±
±
±
±
±
±
±
±
±

ΔΔE
5.1
5.0
6.8
3.7
6.8
5.6
6.8
4.5
3.4
6.1
9.0

25.8
65.9
0.0
13.3
17.7
3.9
36.7
5.6
8.9
18.5
11.9

a
ΔVDW = change of VDW energy in gas phase upon complex formation (unit: kcal/mol). bΔSUR = change of energy due to surface area change
upon complex formation (unit: kcal/mol). cΔEBELE = change of GB reaction ﬁeld energy + gas phase elec. energy upon complex formation (unit:
kcal/mol). dΔCONF = change of conformational energy upon complex formation (unit: kcal/mol). eΔTOT = ΔVDW +ΔSUR + ΔEBELE + ΔCONF change
of potential energy in water upon complex formation (unit: kcal/mol). fΔΔE = ΔTOT − (−96.2).

binding pose as well as a ﬁgure of the ﬁnal binding poses of
each trajectory is available in Figures S7 and S8−S11,
respectively.
The most stable complexes (Figure S13) of the 20
trajectories were extracted and categorized into structural
families on the basis of a clustering analysis for each ligand, as
described in the methods section. By setting the threshold of
1% population, 6 structural families were identiﬁed for
telomestatin (Figure S14), 9 were for TMPyP4 (Figure S15),
10 were for BSU6037 (Figure S16), and 12 were for
BRACO19 (Figure S17). Then, these families were further
merged into three binding modes: interface interacting,
quadruplex side binding, and duplex side binding. After
analyzing each of the modes, it was discovered that only
TMPyP4, BSU6037, and BRACO19 were observed in interface
interacting, quadruplex binding, and duplex binding modes:
telomestatin was not able to bind to or interact with the
interface (Figure 5), and BSU6037 was the only ligand able to
fully intercalate into the interface (Figure 7). The results,
including percentages, of the most abundant clusters are
reported in Figure 4. For telomestatin, overbinding to ends of
the DNA duplex could be a simulation artifact due to the
missing T1 in the crystal structure. The hydrogen bond
networks of the interface interacting modes as well as detailed
two-dimensional ligand−DNA interactions of the major
binding modes are presented in Figures S18 and S19,
respectively.
From the trajectory and clustering analysis, it is clear that
unlike BSU6037, the ligands TMPyP4 and BRACO19 did not
fully intercalate into interface. Instead, TMPyP4 and
BRACO19’s side chains extended into the interface to make
contact. As the interface opened up, the drugs were able to
move further into the interface and the interactions with the
interface were enhanced as the DNA deformed, which suggests
an induced ﬁt binding mechanism. However, despite the
utilization of an induced ﬁt binding mechanism, the ﬁnal
binding mode remained a partial interaction and not full
intercalation for both TMPyP4 and BRACO19.
MM-GBSA Binding Energy Data Showed That the
Interface Interaction Mode of TMPyP4 Was the Most
Energetically Favorable, the G-Quadruplex Binding
Mode of Telomestatin Was Much More Favorable
Than Its Duplex Binding Mode, and the Interface
Interactions of BSU6037 and BRACO19 Were Compa-

A19, T7−A8) and the Two Termini of the Duplex Part
(A25 and A2) had Larger Local Fluctuations Than Those
of the Four G Strands (G1−G3, G5−G7, G9−G11, and
G14−G16) for the DNA-Only System. Figure 3 shows
RMSF plot for the ﬁve systems. As to the DNA-only system
(black line), ﬁve peaks were identiﬁed, corresponding to T4,
T8, T12−T13, T18, and A25−A2. In contrast, the other
regions (G1−G3, G5−G7, G9−G11, G14−G16, G20−T24,
and A3−C6) show lower RMSF values. Thus, although the
four G4 strands and two helical strands had lower structural
ﬂuctuation, the three loops in the G-quadruplex part, the
interface region, and the termini of the duplex part had larger
structural ﬂuctuation. The G-quadruplex top binding by
telomestatin (red line) slightly reduced the RMSF values at
the ﬁve peaks, in particular, the T12−T13 loop peak and the
A24−A2 terminal peak, indicating the telomestatin might
slightly stabilize the overall structure. The interface interaction
by TMPyP4 (green line) slightly reduced the ﬁrst three peaks
but signiﬁcantly reduced the fourth peak in the interface
region. The interface interaction by BRACO19 (blue line)
slightly reduced the ﬁrst three peaks but signiﬁcantly reduced
the fourth and ﬁfth peaks. Thus, the binding by TMPyP4 and
BRACO19 stabilized the interface region. The interface
binding by BSU6037 (purple line) slightly increased the ﬁrst,
second, and ﬁfth peaks but signiﬁcantly reduced the third peak
and shifted the fourth peak to G20−C21 region. These
changes can be attributed to the change of the interface by the
BSU6037 interface binding (Figure 7).
Three Major Binding Modes Were Observed for
TMPyP4, BSU6037, and BRACO19: Interface Interaction,
Binding to the Quadruplex, and Binding to the Duplex,
but No Interface Interaction Mode Was Observed for
Telomestatin. Starting from the unbound state, 20 binding
simulation runs (500 ns of each) were carried out using each
ligand. The RMSD of the DNA backbone heavy showed that a
majority of the trajectories for each complex reached and
remained in a stable form (Figure S4). Those that experienced
a larger ﬂuctuation in RMSD values were those where the
DNA backbone started to slightly unravel and unfold. The
convergence of the binding simulations was conﬁrmed, as
described in the Methods section, with the simulation systems
reaching a relatively steady state where the DNA−ligand
complex retained 20 or more atom contacts (Figure S5). A
table to summarize the number of trajectories in each ﬁnal
14793

DOI: 10.1021/acsomega.8b01574
ACS Omega 2018, 3, 14788−14806

ACS Omega

Article

rable to the Duplex Binding Mode. To examine the
relative stability for the three binding modes observed, MMGBSA binding energy calculations were conducted on each
binding mode for each complex (Table 2). TMPyP4 had the
highest binding energy for interface interaction, −96.2 ± 6.8
kcal/mol, which was 13.3 kcal/mol higher than that for Gquadruplex binding and 17.7 kcal/mol higher than that for
duplex binding. These values indicate that TMPyP4 strongly
interacts with the interface and is selective over the duplex
DNA. Telomestatin did not interact with the interface but had
a much stronger binding energy and selectivity to the Gquadruplex (−70.4 ± 5.1 kcal/mol) over the duplex (−30.3 ±
5.0 kcal/mol). BSU6037 and BRACO19 both had similar
interface interaction and duplex binding energies and a lower
comparative G-quadruplex binding energy. To further understand the nature of binding, the binding energy was broken
down into van der Waals (VDW) interactions, hydrophobic
interactions (SUR), electrostatic interactions (GBELE), and
the conformational energy change induced from the complex
forming (CONF) (Table 2). As shown in Table 2, a majority
of the binding energy is contributed by the VDW energy and
the conformational energy change. As expected, the top
stacking for telomestatin had a higher VDW energy than the
duplex binding; this is likely due to the uniplanar structure of
telomestatin, making stacking a more favorable binding choice.
TMPyP4 had the largest VDW energy for the interface
interaction mode, which could be tied to its charged planar
structure. Both linear structures, BSU6037 and BRACO19, had
higher VDW energies for the duplex and interface than the Gquadruplex, which could be explained by the fact that the linear
structures can better bind to the duplex groove or to the
interface pocket than to the quadruplex loops or top (stacked).
Both planar structures, telomestatin and TMPyP4, had larger
conformational energies for the G-quadruplex than either the
interface or duplex, likely due to their ability to stack on top of
the quadruplex to further stabilize the complex. These large
conformational binding energies further support the induced ﬁt
binding mechanism of the ligands to the quadruplex−duplex
DNA. Each of the four ligands varied in their respective
charged state; telomestatin had no charge (charge state of 0),
TMPyP4 carried the largest charge (+4), BSU6037 had a
charge state of +2, and BRACO19 had a charge state of +3.
The MM-GBSA binding energy data revealed that BRACO19
exhibited the strongest electrostatic interactions (ΔEGBELE)
with the hybrid quadruplex−duplex DNA, indicating that a
charge state of +3 is the best.
Statistics of the interface interacting trajectories are
presented in Table 3. This table provides insight on the
overall binding pathways for the trajectories that maintained a
ﬁnal interface interaction binding pose. Some trajectories were
not included from this analysis, despite making contact with
the interface at some point during the trajectory. For TMPyP4

runs 3 (Figure S22) and 5 (Figure 6), the initial contact with
the DNA is with a residue on a side loop of the quadruplex. In
both cases, within 40 ns after the initial contact, the ligand
relocates closer to the interface where its aromatic side chains
ﬁrst make contact with interface residues. The ligand makes
minor adjustments to maximize interactions with the interface
but remains in the same binding mode for the remainder of the
trajectory. BSU6037 system runs 7 (Figure S25) and 19
(Figure 7) make initial contact with the loop residues on the
quadruplex region before interacting with residues of the
duplex region. In both trajectories, the ligand proceeds to
interact with terminal residue of the interface, which induces
conformational changes to the DNA, moving the ligand inside
of the binding pocket, increasing its interaction with the
interface until ligand stacking is achieved. BRACO19 made
initial contact with the duplex in runs 6 (Figure 9), 8 (Figure
S28), and 10 (Figure S29). After initial contact, the side chains
of BRACO19 made contact with the interface while still bound
to the duplex until the ﬁnal pose was achieved.
To Characterize the Binding Pathway of the Two/
Three Modes of Each Ligand, Seven Order Parameters
Were Calculated for Representative Trajectories, As
Described in the Methods Section (Figures 2, Figures
5−8, and S20−S31). The plots are included in the
supporting document for telomestatin (the quadruplex binding
mode (Figure S20) and the duplex binding mode (Figure
S21)), TMPyP4 (the interface binding mode (Figure S22), the
G-quadruplex binding mode (Figure S23), and the duplex
binding mode (Figure S24)), BSU6037 (the interface binding
mode (Figure S25), the G-quadruplex binding mode (Figure
S26), and the duplex binding mode (Figure S27)), and
BRACO19 (the interface binding mode (Figures S28 and
S29), the G-quadruplex binding mode (Figure S30), and the
duplex binding mode (Figure S31)). A representative
trajectory for each ligand (the quadruplex binding mode for
telomestatin and the interface interacting mode for TMPyP4,
BSU6037, and BRACO19) was selected to be extended from
500 to 2000 ns for checking the stability of these binding
modes. The information gathered from the 2000 ns
simulations is reported in Figures 5−8. The occupancy time
for the ﬁnal stable binding mode was identiﬁed from the
RMSD plot with reference to the ﬁnal snapshot: ∼1800 ns for
telomestatin, ∼1750 ns for TMPyP4, ∼1200 ns for BSU6037,
and ∼1200 ns for BRACO19.
Top Stacking Binding Mode of Telomestatin Provides Support for the Selectivity of This Ligand to the
G-Quadruplex DNA over Duplex DNA. Telomestatin was
unable to bind to or interact with the interface in any of the
simulation runs, but it did bind very selectively to the top of
the quadruplex over the duplex, which is qualitatively
consistent with the experimentally observed 70-fold selectivity
(Table S1). In the representative trajectory (Figure 5),
telomestatin initially contacted the DNA at 14 ns, binding to
the side loop of the quadruplex. It released from this position
at 67 ns and randomly searched for another binding pose until
105 ns, where it slightly moved up and rebound to the
quadruplex side loop. It moved out and stacked on top of the
quadruplex at 165 ns and remained in this top stacking binding
mode for the remaining time. No signiﬁcant changes in the
number of hydrogen bonds were observed in either the Gquadruplex, duplex, or interface, demonstrating that it was not
an induced ﬁt binding mechanism. The two potassium cations
maintained their position and distance throughout the

Table 3. Statistics of the Interface Interacting Trajectoriesa
system

total
interface
interactions

TMPyP4
BSU6037
BRACO19

2
2
3

quadruplex
to interface

duplex
to
interface

quadruplex + duplex
to interface

2
2
3

a

Provided is the overall binding pathway taken by each ligand in its
interface interacting mode.
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Figure 5. Representative trajectory of the top stacking mode of telomestatin (run 9) and the order parameter plot, illustrating the breaking and
reforming of hydrogen bonds (at the quadruplex (1), interface (2), and duplex (3)), drug-base dihedral angle (4), ligand (black)/DNA (red)
RMSD (Å) with reference to the ﬁnal structure (5), ligand center-to-DNA center distance (black) and K+-to-K+ distance (red) (6), and the MMGBSA binding energy (ΔE in kcal/mol) (7). 5′ and 3′ of the DNA chain are indicated by a red and blue ball, respectively. K+ ions are indicated by
yellow balls.

TMPyP4 Interface Interaction Follows a Base “FlipInsertion” Binding Mechanism. TMPyP4 demonstrates a
subtle induced ﬁt binding mechanism. In the representative
trajectory (Figure 6), TMPyP4 made initial contact with the
DNA at the side loop of the quadruplex at 4 ns. At 37 ns,
TMPyP4 shifted down toward the top of the duplex, with a
region of the ligand making contact with the A7 and T19 base
pair of the interface, breaking the two hydrogen bonds shared
between them. By examining the trajectory, we discovered that
the initial interface contact is concurrent with the ﬂipping out
of base T19, creating a binding pocket to allow entrance of the
ligand into the interface region. One hydrogen bond between
the base triad (T8, A18, and T17) also gets disrupted by this
initial interface contact. TMPyP4 moves further into the
interface at 255 ns, completely disrupting all hydrogen bonds
within the base triad. These bases that made up the base triad
in the interface ﬂip out and bond to the aromatic regions of
TMPyP4, such as the methylpiperidine side chains positioned
around the central aromatic ring, rather than to each other.
After this interaction, the top layer of the quadruplex has an
increase in the number of hydrogen bonds but it also exhibits a
higher ﬂuctuation in them; these large ﬂuctuations indicate
that when TMPyP4 moves further into the interface and
maintains a partial intercalation, it does not stabilize the Gquadruplex as much as the initial interface interaction does.
The middle layer of the quadruplex experiences a loss of a

trajectory. The MM-GBSA calculated binding energy revealed
that telomestatin top stacking to the quadruplex (∼−70 kcal/
mol) was more favorable than binding to the side loop of the
quadruplex (∼−30 kcal/mol), which can help explain why this
interconversion occurred.
Binding Mechanism of the Ligands to the Interface
Seems to Be via an Induced Fit Binding Mechanism
Rather Than a “Lock−Key” Binding Mechanism. The
interface interaction modes for TMPyP4, BSU6037, and
BRACO19 are presented in Figures 6−8. The pattern changes
in the number of hydrogen bonds for the interaction of the
three ligands at the interface are consistent with the trajectories
(Figures 6−8). A decrease in the number of hydrogen bonds
among the base triad (red) and base pair (green) was observed
during initial ligand−interface interaction. The hydrogen
bonds for the A7−T19 base pair were completely disrupted
for each interface interaction. The energetic cost of breaking
these hydrogen bonds was likely compensated by the favorable
ligand−interface interaction energy gain. During the interactions, a portion of the ligands were also extended to group
bind to the sides of the DNA backbone adjacent to the
interface. The stacking between the bases and the interacting
portion of the ligands in addition to the group binding between
the extended ligand portion and the DNA is likely further
stabilizing the complex.
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Figure 6. Representative trajectory of the interface interacting mode of TMPyP4 (run 5) and the order parameter plot, illustrating the breaking and
reforming of hydrogen bonds (at the quadruplex (1), interface (2), and duplex (3)), drug-base dihedral angle (4), ligand (black)/DNA (red)
RMSD (Å) with reference to the ﬁnal structure (5), ligand center-to-DNA center distance (black) and K+-to-K+ distance (red) (6), and the MMGBSA binding energy (ΔE in kcal/mol) (7). 5′ and 3′ of the DNA chain are indicated by a red and blue ball, respectively. K+ ions are indicated by
yellow balls.

binding pocket. The binding energy of the interface (−92.3 ±
5.6 kcal/mol) was much larger than that of the G-quadruplex
(−59.5 ± 6.8 kcal/mol), which could explain why after
BSU6037 made an initial contact with the quadruplex it
inserted itself into the interface instead. These conformational
changes that take place during binding demonstrate the
induced ﬁt binding mechanism that the ligand (BSU6037)
produces.
BRACO19 Also Interacted with the Interface Region.
BRACO19 demonstrates another subtle induced ﬁt binding
mechanism. In the representative trajectory (Figure 8),
BRACO19 bound to the major groove of the duplex part at
3 ns where the N,N-dimethylcyclohexylamine side chain made
the initial contact with the side of the quadruplex where it
remained until 107 ns. At 107 ns, a side chain of BRACO19
began making contact with the interface residues T17, A18,
and T19. This side chain binding to the interface region forced
base A7 to ﬂip out, eliminating the hydrogen bonds formed by
the A7−T19 base pair so that the drug moved up and
interacted with the interface region until 767 ns. At 767 ns, the
interface region bends open, allowing the N,N-dimethylcyclohexylamine side chain of BRACO19 to reposition slightly
deeper into the interface region. BRACO19 maintained this
interaction with the interface region throughout the simulation; the G-quadruplex part was stable through the trajectory.
The top potassium cation moved out of the quadruplex at

hydrogen bond during this same period. No signiﬁcant change
in hydrogen bonds is present within the duplex, as the
conformation of this region does not undergo any major
changes. The top potassium ion moved out at 339 ns, whereas
the bottom potassium ion remained stable throughout the
course of the trajectory.
Interface Intercalation of BSU6037 Requires the DNA
To Open Up at the Interface Region To Provide the
Ligand Access to the Binding Site. The binding
mechanism of BSU6037 to the interface is particularly
interesting as it clearly demonstrates an induced ﬁt binding
mechanism (Figure 7). In the representative trajectory,
BSU6037 initially binds to the side of the duplex until 82 ns
where it makes the ﬁrst contact with the interface residues.
BSU6037 binds to terminal residue A8 that ﬂips into the core
of the interface, moving BSU6037 closer into the interface
where it is able to interact with interface residue T19 where it
remains until 300 ns. At 301 ns, the duplex begins to unravel
until 483 ns where it is approximately 90° from the starting
position. At 458 ns, the top potassium cation leaves the
quadruplex. With BSU6037 in the interface, the duplex reforms
itself until complete at 584 ns where BSU6037 remains
stacking in the interface for the remainder of the trajectory.
Under further examination, it was discovered that when the
BSU6037 ligand bonded to the interface of the DNA, it forced
the bonds in the base pair and base triad to break, unfolding
and opening the DNA up, which allowed the ligand into the
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Figure 7. BSU6037, run 19, trajectory snapshots and the order parameter plot, illustrating the breaking and reforming of hydrogen bonds (at the
quadruplex (1), interface (2), and duplex (3)), drug-base dihedral angle (4), ligand (black)/DNA (red) RMSD (Å) with reference to the ﬁnal
structure (5), ligand center-to-DNA center distance (black) and K+-to-K+ distance (red) (6), and the MM-GBSA binding energy (ΔE in kcal/mol)
(7). 5′ and 3′ of the DNA chain are indicated by a red and blue ball, respectively. K+ ions are indicated by yellow balls.

the ligands binding to the DNA induced a large change in each
complex’s conformational energy, which was a major
contributor to the high total energies. Large conformational
binding energies are concurrent with an induced ﬁt binding
mechanism occurring. The DNA subtly opening up at the
interface region makes room for the drug interactions (Figures
6−8). Once the insertion is completed, the interface closes and
the complex is stabilized. Energetically, the loss of hydrogen
bonds at the interface is compensated by the initial ligand−
DNA interaction and ﬁnal π−π interactions once the induced
ﬁt mechanism is completed. Of course, more experimental
evidence is required to support this interface open-close
mechanism.
Out of multiple major binding poses for each system, our
MM-GBSA binding energy calculations indicate that interface
interactions were the most stable binding pose. The large
magnitude of the binding energy in combination with the long
time (2000 ns) stability suggests that the binding is likely
enthalpically driven, with a minor contribution in regard to the
entropic binding energy. The binding energy decomposition
analysis further suggests that the VDW and CONF terms make
the largest contributions to the total binding energy. This
indicates that drug speciﬁc packing optimization is a possible
way to further stabilize G-quadruplexes.
MM-GBSA binding energy calculations indicate that the
most stable binding pose for telomestatin was top stacking to
the G-quadruplex; its large uncharged planar structure was

1636 ns. MM-GBSA calculations determined that the binding
energy ﬂuctuated between −80 and −90 kcal/mol.

■

DISCUSSION
G-quadruplex DNA has become an important therapeutic
target recently as it has been found to be over-represented in a
wide variety of cancers.84 Many ligands targeting Gquadruplexes have been developed; however, selectivity to a
speciﬁc G-quadruplex over DNA duplex is yet to be achieved
at a level acceptable for therapeutic use. Recently, the junction
between the G-quadruplex and duplex hybrid DNA (PDB:
5DWW) in the 3′ end of telomeric overhang was targeted as a
promising opportunity to improve upon G-quadruplex
selectivity and ligand potency.46 Yet, there are no detailed
molecular interactions or high-resolution complex structures
reported for most of the ligands except for BSU6037,46 which
has been docked to the crystal structure of the G-quadruplex−
duplex hybrid.
This study was done to gain molecular insights into the
binding of telomestatin, TMPyP4, BSU6037, and BRACO19
to the quadruplex−duplex DNA by using binding molecular
dynamic simulations with a free ligand. The free ligand
simulation allowed for more dynamics and ﬂexibility within
both the DNA and ligand, which in turn showed that ligand
interaction with the interface was by means of an induced ﬁt
binding mechanism rather than a lock−key mechanism. The
MM-GBSA binding energy calculations (Table 2) showed that
14797

DOI: 10.1021/acsomega.8b01574
ACS Omega 2018, 3, 14788−14806

ACS Omega

Article

Figure 8. BRACO19, run 06, trajectory snapshots and the order parameter plot, illustrating the breaking and reforming of hydrogen bonds (at the
quadruplex (1), interface (2), and duplex (3)), drug-base dihedral angle (4), ligand (black)/DNA (red) RMSD (Å) with reference to the ﬁnal
structure (5), ligand center-to-DNA center distance (black) and K+-to-K+ distance (red) (6), and the MM-GBSA binding energy (ΔE in kcal/mol)
(7). 5′ and 3′ of the DNA chain are indicated by a red and blue ball, respectively. K+ ions are indicated by yellow balls.

Figure 9. Suggested modiﬁcations for telomestatin and TMPyP4.
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The MM-GBSA binding energy analysis revealed that
BSU6037 bound to the interface and duplex at comparable
binding energies (∼−91.5 kcal/mol), which was about 30
kcal/mol stronger than binding to the quadruplex part.
Similarly, BRACO19 interacted with the interface and bound
at the duplex at comparable binding energies (∼−86.6 kcal/
mol), which was around 10 kcal/mol stronger than binding to
the quadruplex. Not only do these ligands lack selectivity over
duplex DNA, they also bind to the interface weaker than
TMPyP4 between 3.9 and 8.9 kcal/mol. Interestingly, despite
BSU6037’s ability to intercalate into the interface, the partial
interaction between TMPyP4 and the interface remains more
energetically favorable. These ﬁndings indicate that linear
structures, even those that contain charged side chains, lack the
selectivity and potency needed to be a viable G-quadruplex
stabilizer. Therefore, future ligand development should focus
on charged aromatic scaﬀolds that optimize packing and π−π
interactions within the interface and include charged side
chains that destabilize the DNA backbone to allow the ligand
entrance to the interface binding pocket.
The free binding simulations also revealed that BSU6037
had a diﬀerent binding pose than the one described by Krauss
et al. in 2016. Krauss et al. found that a pseudo binding site for
BSU6037 could be constructed at the interface region by
disrupting T17 of the TAT base triad, which consists of bases
T17(A)−A18(A)−T8(B), to expose the surface of the bottom
G-quartet; speciﬁcally, they thought that if T17 of the base
triad ﬂipped out, the ligand would have access to the bottom of
the quadruplex.46 When they docked BSU6037 into this
pseudo binding site, the ligand ﬁt directly below the bottom Gquartet, with the ligand oriented so that it laid in-plane with
the A7−T19 base pair. However, the free ligand molecular
dynamic simulations in this work did not show BSU6037
binding in this position. BSU6037 destabilized DNA at the
interface region, causing bases T7 and A8 to break apart from
their respective partners and ﬂip out, which in turn unfolded
the DNA at the interface. BSU6037 ﬁt into the opened binding
pocket, and the DNA refolded around it (Figure 7).
Furthermore, the simulations resulted in BSU6037 experiencing slightly diﬀerent interactions then what was observed in the
docked experiments. In the previous docking experiment, the
central planar regions of BSU6037 exhibited π−π stacking
interactions with bases G11, G16, and T17, the center
protonated nitrogen of BSU6037 had a hydrogen bond with
the N1 atom of base T19, the side chain amide nitrogen had a
hydrogen bond with the carbonyl oxygen atom (O4) of base
A8, and the other side-chain amide nitrogen had a hydrogen
bond with the N3 atom of base A18.46 In this work, π−π
stacking interactions with the central planar regions of
BSU6037 and bases G11 and A8 on the 3′ end of the shorter
DNA strand were observed, as well as a hydrogen bond was
formed between the side-chain amide nitrogen and base T17.
This change in ligand−DNA interactions is likely brought on
by the diﬀerent binding location of BSU6037.
Coordination of O6 carbonyls by cations within the ion pore
is known to be a major factor in stabilizing the quadruplex
structure. Successful stabilization from the cations has
reportedly maintained an average interquartet distance of 3.3
Å between the bipyramidal antiprism that is formed.83 Zheng
and co-workers85 have shown that single-strand G-rich
sequence can fold into a G-quadruplex with very low K+-ion
concentration (0.01−01 mM), indicating strong binding of K+.
To look into this feature, distance calculations were performed

better suited to stacking on top of the G-quadruplex, as top
stacking results in the most favorable packing interaction.
However, telomestatin did not bind to or interact with the
interface. Because the other three charged ligands were found
to be able to interact with the interface, it is speculated that
lack of charge for telomestatin might hinder its ability to
interact with the DNA backbone for opening the binding
pocket and interacting with the interface. If this is true, the
ﬁndings of this work suggest that to allow telomestatin to bind
at the interface region and maintain its high selectivity over
duplex DNA, the planar scaﬀold needs to incorporate some
small charged side chains (Figure 9 top). These charged side
chains can disrupt the DNA backbone interactions, thereby
destabilizing the DNA scaﬀold enough to allow a binding
pocket to open up and permit ligand insertion into the
interface.
To test this, induced ﬁt docking was performed on the
original ligand, telomestatin, as well as a modiﬁed ligand
containing two charged side chains (Figure S32a−d). The
results of the induced ﬁt docking revealed there was a −3.1
kcal/mol diﬀerence between the original ligand (−7 kcal/mol)
and the modiﬁed ligand (−10.1 kcal/mol) binding energies.
This supports the proposed modiﬁcation that adding a small
charged side chain would increase the ability of the ligand to
insert into the interface. Nonetheless, further simulation and
experimentation are required to verify the proposed
modiﬁcation.
TMPyP4 exhibited the highest interface MM-GBSA binding
energy (−96.2 kcal/mol), which was the strongest binding
energy of all binding modes among the four ligands. In fact, the
MM-GBSA binding energy shows that the interface interaction
mode is signiﬁcantly more stable for TMPyP4 than the
quadruplex and duplex binding modes by 13.3 and 17.7 kcal/
mol, respectively, indicating that the interface mode may
signiﬁcantly contribute to the higher aﬃnity as well as a higher
selectivity to the 3′ telomeric quadruplex−duplex junction.
However, TMPyP4 has a preference to bind to diad base over
quartet due to its size and structure and it only interacts with
the interface partially when the interface is completely
distorted. It is clear that the size and charge of TMPyP4
hindered the ligands ability to fully intercalate into the
interface so that the central chromophore could interact with
both the bottom quartet of the G4 as well as the top diad of
the duplex inside of the interface simultaneously; this was also
the case for BRACO19. Therefore, it is speculated that the
methyl groups of TMPyP4 should be removed from the
aromatic side chains to increase stability and allow the ligand
to move deeper into the interface to increase ligand−DNA
interactions. The proposed structure (Figure 9 bottom) is
designed to keep TMPyP4 intact and to increase packing
interactions with a deeper insertion of the drug into to the
interface (Figure S32E−H). This could potentially create more
potent and selective ligands to bind to the interface of the Gquadruplex−duplex hybrid DNA. As a result of induced ﬁt
docking, the proposed structure had a docking score of −12.81
kcal/mol, which is 0.37 kcal/mol stronger than that of the
original structure. The proposed TMPyP4 analog showed an
increase in its ability to remain planar and increase the
interactions with the interface (Figure 32H). This supports the
proposed modiﬁcation to the original ligand to increase the
ligands ability to move deeper into the interface. Nonetheless,
further simulation and experimentation are required to verify
the proposed modiﬁcation.
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to deﬁne some parameters of the K+ cations relative to the
surrounding G4 DNA. Analyzing the oxygen−potassium and
oxygen−oxygen distance calculations (Figure S1; Tables S2,
S3, and S6) revealed that each residue was able to maintain an
average oxygen−oxygen distance close to 3.3 Å during the
simulations. The similar mean values and very low standard
deviations for both calculations indicate that the simulation
parameters for the K+ cations are appropriately set despite the
K+ cation moving out of the ion pore in some ligand binding
trajectories. Because none of the K+ moved out in three 2.0 μs
simulations of the DNA-only system, the ligand binding might
lead to the increase of the dynamic ﬂuctuation of the
quadruplex and the K+-ion pore. In fact, the trajectory analysis
indicates that the moving out of a K+ ion occurred at the
induced ﬁt binding process with a large deformation of the
DNA structure. It is suspected that further extending the
simulation period may show the reversible binding of the K+
cation into the ion pore as the DNA structure is stabilized from
the ligand binding. In future work, a more detailed analysis can
be performed to elucidate the dynamic properties of the
reversible binding of K+ cations.
Literature suggested the H-rise and H-twist geometry
parameters were the most important parameters to analyze
the overall helical structure. Despite a number of works
deﬁning duplex DNA, there has been little research into the
helical rise and rotation of the quadruplex structure from the
simulations. This research was able to identify average values
for the H-rise (2.4 Å) and H-twist (20 Å) of the bases within
the three quartets of the DNA G-quadruplex, as well as
reproduce an average value for the rise parameter (3.5 Å). A
common feature deﬁning helical B-DNA is maintaining average
values of 3.32 Å and 34.3° for H-rise and H-twist, respectively.
The results of the H-rise and H-twist helical geometry
parameter analysis revealed comparable values for each of
the systems being analyzed, providing quantitative support that
the helical structure was maintained throughout the simulations.
In addition to the interface interacting mode, a top stacking
mode on the parallel G-quadruplex part for TMPyP4 and
BRACO19 was also observed (Figure 4). Interestingly, their
complex crystal structure with a two-stranded parallel human
telomeric G-quadruplex are available in the PDB databank.32,86
(Figure 10). Although the number of strands forming the
parallel G-quadruplex is diﬀerent, the binding mode from the
simulations shows a good similarity to the crystal structure.
This supports the simulation methodology in this study.

Figure 10. Comparison of the G-quadruplex end binding mode from
the ligand binding simulations and from the crystallography studies. 5′
and 3′ are represented by red and blue balls, respectively. Potassium
cations are represented as yellow balls.

interacting, quadruplex side binding, and duplex side binding.
The MM-GBSA binding energy analysis revealed that of the
three binding modes, the interactions with the interface region
of the quadruplex−duplex hybrid DNA would result in the
most stable structure. The MM-GBSA binding energy analysis
also revealed that TMPyP4 has the strongest binding energy to
the interface region. The trajectory analysis revealed that
TMPyP4, BSU6037, and BRACO19 were able to interact with
the interface via an induced-ﬁt mechanism, consistent with
subtly opening near the interface and repacking after ligand
insertion. However, BSU6037 was the only ligand able to
remain fully intercalated into the interface region. Both linear
ligands BSU6037 and BRACO19 were not selective over
duplex DNA. The results of the induced ﬁt docking suggest
that removal of the methyl groups from the aromatic side
chains of TMPyP4 could allow the central ring to interact
deeper within the interface region; the docking also suggests
that adding some small charged side chains to telomestatin’s
aromatic scaﬀold may allow this ligand to interact with the
interface region. With these ﬁndings, it is believed that further
research in increasing the binding stability could result in
promising telomeric G-quadruplex−duplex stabilizers.

■

CONCLUSIONS
Computational methods have become essential in drug
discovery as they provide the detailed structural information
that experimental results may lack. Although many Gquadruplex ligands have been designed, they still lack the
potency and selectivity to a speciﬁc G-quadruplex over duplex
DNA that is required for therapeutic use. A promising
opportunity to improve upon both selectivity and potency is
by targeting the recently solved junction between Gquadruplex−duplex hybrid DNA in the 3′ end of telomeric
overhang. In this study, free ligand molecular dynamic
simulations were utilized in addition to MM-GBSA binding
energy calculations to evaluate the binding modes and
mechanisms of telomestatin, TMPyP4, BSU6037, and
BRACO19, which have had little research previously done.
Three diﬀerent major binding modes were identiﬁed: interface

■

METHODS
Simulation System. Three types of systems were
constructed: a DNA-only, a ligand-only, and four DNA +
ligand (Table 1). The unbound DNA−ligand system was
constructed using the X-ray crystallography solved human
telomeric G-quadruplex−duplex structure (PDB ID:
14800
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5DWW46), including the K+ ions inside the G-quadruplex and
a ligand molecule that was at least 10 Å away from the DNA.
The 10 Å distance makes sure that there are at least three
layers of water molecules separating the ligand from the DNA;
therefore, there is not much interaction between the ligand and
the DNA (i.e., an unbound state). This setup allowed the
probing of the binding pathways and binding mechanisms.
This unbound system (DNA plus ligand) was solvated in a
water box of truncated octahedron with 10 Å water buﬀer plus
K+ as counter ions to neutralize the system, leading to ∼120
mM of K+ cation concentration. The latest version of the
AMBER DNA OL15 ﬀ99 (i.e., parm99bsc087 + χOL488 + ε/
ζOL189 + βOL190 updates) was applied to represent the DNA,
TIP3P model91 was used to represent water, and the recently
developed K+ model by Cheatham group was used for the
system.92 The partial charges for each ligand molecule were
obtained using standard AMBER protocol: the electrostatic
potential of the ligand molecule was obtained at the HF/631G* level after geometry optimization at the same level; the
electrostatic potential using the restrained electrostatic
potential method determined the partial charges,93 and other
force-ﬁeld parameters were taken from the AMBER GAFF294
force ﬁeld. The ligand force ﬁeld in Mol2 format can be found
in the supporting document (Figure S33). These AMBER
force ﬁelds are the most common ones used in nucleic acid
simulations including G-quadruplexes.80,82,88,95−99
Simulation Protocols. Three runs for the DNA-only, ﬁve
runs for the ligand-only, and the 20 simulation runs for each
unbound DNA−ligand system (Table 1) were conducted
using the GPU version of the AMBER 14 simulation
package.100 The detailed protocol followed this groups’ early
studies.101,102 Each unbound DNA−ligand system underwent a
500 ps prerun at 500 K to ensure the position and orientation
of the free ligand was randomized before a production run at
300 K; during this prerun, the receptors’ position remained
ﬁxed. After the energy minimization for the initial structure of
a system, 3, 5, or 20 independent runs were performed by
assigning diﬀerent initial velocities to the atoms of the system;
this was followed by a Maxwell−Boltzmann distribution using
a diﬀerent random seed. The multiple independent runs for the
DNA−ligand system allow for a better sampling of binding
poses and pathway. A production run of 500 ns at 300 K
included a short 1.0 ns molecular dynamics run in the NPT
ensemble mode (constant pressure and temperature) to
equilibrate the system density in which the DNA and ligand
were subjected to Cartesian restraints (1.0 kcal/mol Å) and
499.0 ns dynamics in the equivalent NVT ensemble mode
(constant volume and temperature) (Table 1). SHAKE103 was
applied to constrain all bonds connecting hydrogen atoms,
enabling a 2.0 fs time step in the simulations. The particlemesh Ewald method104 was used to treat long-range
electrostatic interactions under periodic boundary conditions
(charge grid spacing of ∼1.0 Å, the fourth order of the B-spline
charge interpolation, and direct sum tolerance of 10−5). The
cutoﬀ distance for short-range nonbonded interactions was 10
Å, with the long-range van der Waals interactions based on a
uniform density approximation. To reduce the computation,
nonbonded forces were calculated using a two-stage RESPA
approach105 where the short-range forces were updated every
step and the long-range forces were updated every two steps.
Temperature was controlled using the Langevin thermostat
with a coupling constant of 2.0 ps. The trajectories were saved
at 50.0 ps intervals for analysis.

Convergence of Simulations. The root-mean-square
deviation (RMSD) of DNA/ligand backbone heavy was
calculated against the starting structure. The ﬂat and small
average RMSDs (Figures S3 and S4) over all runs indicate that
these systems were stable. Atom contacts between the DNA
fragment and the drug molecule were calculated using an
atom-to-atom distance cutoﬀ of 3.0 Å. The simulation systems
reached a steady state, as indicated by the stable average
contact number (Figure S5) over all runs. A stable complex
was deﬁned as a complex with the number of atom contacts
between the DNA fragment and the drug molecule greater
than 20. The last snap shots of the apo form are shown (Figure
S6).The free drugs bound to diﬀerent sites, as shown in the last
snapshots for the 20 runs (Figures S8−S11), indicate a good
sampling of binding sites.
K+ Position. Distances were calculated to determine the
position of the K+ cation relative to the surrounding DNA Gquadraplex (Figure S1 and Table S6) because the electrostatic
interactions between the K+ cation and the partially negative
oxygen atom on each residue of the surrounding G-quartet are
critical in stabilizing the G-quadruplex structure. For the apo
DNA form, the distance between the oxygen on each residue
and the nearest K+ cation (Figure S1c), as well as the distance
between the oxygen of each residue and the oxygen of the
nearest residue (Figure S1d) was calculated. These oxygen−
oxygen and oxygen−potassium distances per residue were also
calculated for the four ligand binding simulations (Tables S2
and S3).
G-Quadruplex Parameters. To understand inter-G4 layer
geometry, the rise, H-rise, and H-twist parameters were
calculated. The rise parameter was deﬁned as the distance
(Å) between the centers of the guanine bases, excluding the
sugar phosphate backbone, of the lower G4 layer to the center
of the guanine bases on the G4 layer above. The H-rise
parameter calculated the projection of the G4 layer rise with
respect to the Z axis, which was deﬁned as the vertical axis
through the two K+ cations located inside the G4-ion channel.
The H-twist parameter calculated the rotational angle of the
bases with respect to the aforementioned Z axis. The rotation
in the H-twist parameter was calculated from the bottom,
meaning that the layer above would be used as a reference,
measuring the degree of clockwise rotation required of the
lower layer to align with the position of the reference layer
(Table S6).
DNA Duplex Parameters. Various helical parameters were
calculated using Curves+106 to characterize the base pairing in
the helical portion of the DNA (Table S4). The base pair-axis
parameters were used to quantify the rigid-body transformation of the base pair reference frame and the reference
frame of the local helical axis. The base pair-axis parameters
were calculated by measuring the movement of the bases
toward the grooves (x-displacement), movement of the bases
perpendicular to the grooves (y-displacement), rotation around
the short axis of the base pairs (inclination), and rotation
around the long axis of the base pairs (tip). Intrabase pair
parameters were calculated using the rigid-body transformation
from one base reference system to its respective paired base
reference system. The three translational parameters calculated
measured the change in distance with respect to the vector
pointing to the major groove (shear), with respect to the
vector pointing along the long axis of the base pair (stretch),
and with respect to the vector of the base pair (stagger). Three
rotational parameters were also calculated that measured the
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layer that is closest to the drug and the drug’s ring plane. Atom
contact number between the DNA and the drug molecule was
calculated using an atom-to-atom distance cutoﬀ of 3.0 Å.
Ligand−DNA distance was deﬁned as the distance from the
DNA center to the drug molecule center, indicated by a black
line. Potassium-ion distance was deﬁned as the distance from
the center to center of the two potassium ions inside the Gquadruplex, indicated by a red line.
The molecular mechanics generalized born/surface area
(MM-GBSA)108 module in the AMBER package (GB1 model
with Bondi radii set, salt of 0.2 M, and surface tension of
0.0072 kcal/mol/Å2) was used to analyze the energetics of the
bound complexes to avoid the large energy ﬂuctuation of
explicit solvent. A recent evaluation study by Case and coworker has concluded that realistic DNA modeling can be
obtained with GB implicit solvation methods and the GB1
model performs better than GB2-OBC1 and GB5-OBC2.109
Note that the two K+ ions inside the G-quadruplex−duplex
DNA were kept in MM-GBSA calculations because they were a
part of the complex structure. The MM-GBSA binding energy
for a system was calculated from three simulations:110 ligand
only, DNA only, and DNA−ligand complex using eq 1. It has
four components in the eq 2: van der Waals (VDW)
interaction energy, hydrophobic interaction energy (SUR),
electrostatic interaction (GBELE), and the change of the
conformation energy for DNA and ligand. These terms were
calculated using eqs 3 and 4.

rotation with respect to the vector pointing into the major
groove (buckle), pointing along the long axis of the base pair
(propel), and with respect to the vector normal to the base pair
(opening). Another set of parameters calculated was the
interbase pairing parameters that calculated the rigid-body
transformations between base pairing steps. The interbase pair
parameters calculated included three translational parameters
(shift, slide, and rise) and three translational parameters (tilt,
roll, and twist), along with two additional parameters that
considered the rigid body movement of each step relative to
the overall helical axis (H-rise and H-twist).
DNA Backbone Parameters. Backbone torsional angles
(α, β, γ, δ, ε, ζ, χ, Pucker) (Figure S12) were calculated to
further characterize the conformational changes of the DNA in
each system (Table S5). The standard backbone dihedral
angles (α, β, γ, δ, ε, and ζ) were measured around the covalent
bonds of the sugar ring and χ about the glycosidic bond. The
sugar puckering was calculated by determining the position of
the phosphorus atoms relative to the sugars.
Structural Fluctuation of the DNA. For each system, the
root-mean-square ﬂuctuations (RMSFs) of each individual
residue of DNA were calculated to characterize the local
structural ﬂuctuation (Figure 3).
Binding Mode Identiﬁcation. Because the DNA backbone was relatively stable in the binding process, we aligned
the DNA backbone of the stable complexes from the
trajectories by a least square ﬁtting. The aligned complexes
were clustered into diﬀerent structural families on the basis of
the 2 Å pair-wise RMSD cutoﬀ of the drug molecule only using
the Daura algorithm,107 in which the number of neighboring
structures was calculated for every structure on the basis of the
RMSD cutoﬀ. The structure with the largest number of
neighbors together with its neighboring structures was
removed to form a structure family, and the process continued
for the remaining structures until all structures were assigned
to a structural family (Figure S13). The centroid structure (i.e.,
the structure having the largest number of neighbors in the
structural family) was used to represent the family. The
centroid structures of populated structural families (>1% of
total structure population) are shown in Figures S14−S17. On
the basis of visual inspection, the centroid structures were
further merged into superfamilies corresponding to major
binding modes (interface, quadruplex, and duplex binding).
Parameters for Characterizing DNA−Drug Binding
Pathway. Seven order parameters were calculated to
characterize the DNA−drug binding process: hydrogen bond
analysis at the quadruplex, interface, and duplex, drug-base
dihedral angle, ligand RMSD (Å), center-to-center distances
(Å), and MM-GBSA binding energy (ΔE in kcal/mol). The
distance cutoﬀ between H-donor and H-acceptor was 3.5 Å,
and the donor-H-acceptor angle cutoﬀ was 120°. The
hydrogen bonds for the G-quadruplex were calculated for the
top (red; G1, G5, G9, and G14), middle (green; G2, G6, G10,
and G15), and bottom (blue; G3, G7, G11, and G16) Gtetrads over the course of the trajectories (Figure 1A). The
hydrogen bonds for the interface were calculated for the top/
three-base layer (red, T8, T17, and A18) and bottom/two-base
layer (green, A7 and T19) over the course of the trajectories.
The hydrogen bonds for the duplex were calculated for the ﬁrst
(red, C6, and G20), second (green; G5−C21), and third
(blue; C4−G22) base pairs below the interface, over the
course of the trajectories. The ligand-base dihedral angle was
deﬁned as the dihedral angle between the plane of the DNA

ΔE = Ecomplex − E DNA_free − E lig_free

(1)

ΔE = ΔE VDW + ΔESUR + ΔEGBELE + ΔEcomformation

(2)

ΔEx = Ex _complex − Ex _DNA_complex − Ex _lig_complex , x
= VDW, SUR, and GBELE

(3)

ΔEcomformation = E DNA_from_complex + E lig_from_complex
− E DNA_free − E lig_free

(4)

Absolute binding free-energy calculations can be very useful in
determining binding site selectivity in G-quadruplex DNA,
which is not easily obtained through experimental methods.111
However, due to the high computation cost of the absolute
free-energy calculation, the relative free-energy calculation with
implicit solvent model can be useful for screening a large
number of ligands. A recent study has shown that GB models
make good prediction even for charged molecules when the
relative solvation free energy is considered.112 Systematic
benchmarking studies up to 1864 crystal complexes have
shown that relative MM-GBSA binding energy is a powerful
tool to rank ligand binding aﬃnity.113−117 This is also
supported by our previous studies, in which the binding
energy of between anticancer drug doxorubicin and a B-DNA
fragment (d(CGATCG)2),98 between anticancer drug daunomycin and a TGGGT G-quadruplex DNA,118 between RHPS4
and human telomeric G-quadruplexes/duplex,110 between
telomestatin and a hybrid telomeric G-quadruplex,45 and
between BRACO19 and a parallel-stranded telomeric Gquadruplex119 were successfully assessed by this MM-GBSA
protocol.
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